Faes Farma reports high profit, low sales

18 May 2008

Spain's Faes Farma has reported a 20% rise in profit in the first three months of 2008 compared to the year-before period, despite a 3.7% drop in sales due to the early Easter Holidays.

Income rose to 8.1 million euros ($12.5 million) during the quarter, whereas sales dropped to 50.2 million euros. However, the firm maintains this is due to the Easter Holidays being brought forward to March as it reports revenue for April showing an increase in spite of strong compulsory price restrictions.

The disparity between sales and profit is due to a 52% drop in costs for depreciation and amortization due to a redefinition of the useful life of some of the firm's oldest intangible assets, ie, trade marks.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight